Evidence Regarding Pharmacogenetics in Pain Management and Cancer

D. Max Smith; William D. Figg

doi:10.1093/oncolo/oyac277

Evidence Regarding Pharmacogenetics in Pain Management and Cancer

D. Max Smith^*, William D. Figg

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics.This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.

Original language	English
Pages (from-to)	189-192
Number of pages	4
Journal	Oncologist
Volume	28
Issue number	3
DOIs	https://doi.org/10.1093/oncolo/oyac277
State	Published - Mar 2023
Externally published	Yes

Keywords

cancer pain
opioids
pain
pharmacogenetics
pharmacogenomics

Access to Document

10.1093/oncolo/oyac277

Cite this

@article{960fe9c3b3474ac784a9acf7ec132cf3,

title = "Evidence Regarding Pharmacogenetics in Pain Management and Cancer",

abstract = "Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics.This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.",

keywords = "cancer pain, opioids, pain, pharmacogenetics, pharmacogenomics",

author = "Smith, {D. Max} and Figg, {William D.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press.",

year = "2023",

month = mar,

doi = "10.1093/oncolo/oyac277",

language = "English",

volume = "28",

pages = "189--192",

journal = "Oncologist",

issn = "1083-7159",

number = "3",

}

TY - JOUR

T1 - Evidence Regarding Pharmacogenetics in Pain Management and Cancer

AU - Smith, D. Max

AU - Figg, William D.

N1 - Publisher Copyright: © The Author(s) 2023. Published by Oxford University Press.

PY - 2023/3

Y1 - 2023/3

N2 - Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics.This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.

AB - Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics.This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.

KW - cancer pain

KW - opioids

KW - pain

KW - pharmacogenetics

KW - pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=85150665353&partnerID=8YFLogxK

U2 - 10.1093/oncolo/oyac277

DO - 10.1093/oncolo/oyac277

M3 - Review article

C2 - 36718020

AN - SCOPUS:85150665353

SN - 1083-7159

VL - 28

SP - 189

EP - 192

JO - Oncologist

JF - Oncologist

IS - 3

ER -

Evidence Regarding Pharmacogenetics in Pain Management and Cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this